Organigram – Sanity Group Deal: What Changed and What it Means for Germany
This article was originally published in February 2026, and was most recently updated on September 22, 2026.
This article was originally published in February 2026, and was most recently updated on September 22, 2026.
Last week’s rescheduling announcement has placed a spotlight firmly on the medical cannabis arms of North America’s largest operators.
By Dr Sebastian Marincolo, Director of Strategic Content & Editorial, Weed.de Canadian cannabis company Organigram Global has agreed to acquire Berlin’s Sanity Group for up to 227 million euros, financed in large part by a roughly 65 million Canadian dollar capital injection from its largest shareholder, British American Tobacco (BAT).
Last month, the German cannabis market saw its most significant consolidation deal to date, as Canadian heavyweight Organigram announced plans to acquire Sanity Group in a deal worth up to €250m.
Curaleaf Laboratories, one of the UK-leading pharmaceutical-grade medical cannabis manufacturers, is delighted to announce a partnership with Berlin-based Sanity Group, a European life science company focused on cannabinoids and wellbeing products.
The increasingly blurry lines between Germany’s medical and recreational cannabis markets are continuing to cause conflict among lawmakers and industry stakeholders ahead of the upcoming general election.
British American Tobacco [stock_market_widget type=”chart” template=”line” assets=”BATS.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Tobacco giant British American Tobacco (BAT) has announced the launch of a second investment fund as part of its corporate venture arm, Btomorrow Ventures (BTV).
‘The way is clear’ for Germany’s growing list of municipalities, universities and cannabis businesses to launch model research projects into adult-use cannabis.
Last week, Hanover and Frankfurt published ‘letters of intent’ to launch controlled cannabis sales to thousands of participants through new model projects, designed to gather data and inform future drug policy in Germany.